Article
Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Bone - 1 Jun 2016
Lindahl K, Kindmark A, Rubin C-J, Malmgren B, Grigelioniene G, Söderhäll S, Ljunggren Ö, Åström E
Abstract excerpt
BACKGROUND: Osteogenesis imperfecta (OI) is an inherited heterogeneous bone fragility disorder, usually caused by collagen I mutations. It is well established that bisphosphonate treatment increases lumbar spine (LS) bone mineral density (BMD), as well as improves vertebral geometry in severe OI; however, fracture reduction has been difficult to prove, pharmacogenetic studies are scarce, and it is not known at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.